ClinicalTrials.gg
Status unknownNCT00520585ATORVAUpdated Aug 24, 2007

Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes

An interventional study of atorvastatin in Heterogeneity of Cardiomyocytes Repolarisation and Autonomic Changes of Cardiomyocytes Repolarisation, sponsored by Masaryk University. Status unknown. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-08-24.

Sponsored by Masaryk University · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Aug 2007), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The aim of this study is to evaluate influence of atorvastin on the repolarisation phase of cardiomyocytes. If there is any, it could be a part of positive "non-lipid" effect of statins in therapy of ischaemic heart disease.

Study hypothesis: atorvastin will decrease heterogeneity of repolarisation of cardiomyocytes in comparison with placebo

Read the detailed description

The group will consist of 40 healthy volunteers. The study will be mono-centric. The repolarisation phase of cardiomyocytes will be evaluated using long - term 12-lead digital ECG monitoring. There will be 3 single ECG recordings - randomly after 20 mg of atorvastin, 80 mg of atorvastatin and placebo, respectively.

02

Conditions studied

  • Heterogeneity of Cardiomyocytes Repolarisation
  • Autonomic Changes of Cardiomyocytes Repolarisation

Keywords

  • atorvastatin
  • repolarisation
  • cardiomyocytes
03

In context

Lead sponsor

Masaryk University is the lead sponsor of 45 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed informed consent
  • age 18 - 45 years

Exclusion criteria

Exclusion Criteria:

  • no chronic active disease
  • no concomitant pharmacotherapy, excluding hormonal contraception
  • abnormal ECG, echocardiography, laboratory findings
  • known hypersensitivity or myopathy due o statin
  • pregnancy, lactation, breast implants
  • skin disease
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)

Interventions

  • atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo

06

Study locations

No study locations are listed for this record.

07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00520585
Lead sponsor
Masaryk University
First posted
Aug 24, 2007
Start date
Aug 2007
Completion
Nov 2007 (estimated)
Last update
Aug 24, 2007

Study contacts

Ondrej Toman, MD
Contact
ondrej.toman@atlas.cz
+420532232651
Ondrej Toman, MD
principal investigator · University Hospital Brno, Department of Cardiology, Brno, Czech Republic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion